DSIP.
Delta sleep-inducing peptide — slow-wave sleep modulation and stress resilience.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About DSIP.
DSIP (Delta Sleep-Inducing Peptide) is a 9-amino-acid neuropeptide first identified in 1977 in the cerebral venous blood of sleeping rabbits. It has been studied for effects on delta-wave sleep architecture, stress resilience and pain modulation.
The clinical literature is heterogeneous and the receptor is still incompletely characterised. In practice DSIP is used as an adjunct in sleep, stress and chronic-pain protocols.
DSIP modulates GABA-ergic and opioid signalling in the limbic system. It increases the proportion of slow-wave sleep, reduces nocturnal cortisol surges and dampens excessive sympathetic tone.
Subcutaneous injection, typically 100–300 mcg at bedtime.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- INN / Name
- DSIP
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 5mg vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.